Bavarian Nordic has secured a $𝟏𝟓𝟔.𝟖 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 contract from the 𝐔.𝐒. 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 to replenish its supply of the 𝐬𝐦𝐚𝐥𝐥𝐩𝐨𝐱/𝐦𝐩𝐨𝐱 𝐯𝐚𝐜𝐜𝐢𝐧𝐞, 𝐉𝐲𝐧𝐧𝐞𝐨𝐬. Of this, $𝟏𝟑𝟗.𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 will cover the production of vaccine bulk in 2024, with the remaining $𝟏𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 allocated for storage and additional services from 2025 to 2027. This contract supports the U.S.'s preparedness efforts following a 2022 mpox outbreak and continues Bavarian Nordic's longstanding partnership with the Biomedical Advanced Research and Development Authority (BARDA). More info: https://lnkd.in/eUsbay6n #Vaccines #Smallpox #Mpox #PublicHealth #Biopharma #investment
Global Life Science Hub
Staffing and Recruiting
Multidiscipline headhunting firm providing comprehensive consultancy services to the Pharma and Medical Device industry.
About us
With over 20 years of experience across our senior leadership team, The Global Life Science Hub provides functional services and consulting with a solid mission to accelerate, strengthen and enhance global clinical trials. Financially backed by a global specialist head-hunting firm. We are primed to continue the growth and development in the Clinical, Regulatory Quality, Manufacturing and Biometrics sectors to effectively expand our functional services globally. The Global Life Science Hub strives to ensure that all of our clinical research clients can meet their end-point goals by providing a better alternative to recruitment agencies, CROs, CDMOs and other 3rd party vendors.
- Website
-
http://www.glshub.com
External link for Global Life Science Hub
- Industry
- Staffing and Recruiting
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- recruitment, pharmaceuticals, life science, hiring, clinical research, biometrics, project management, central lab, CRO, Pharma, biotech, CRA, clinical research associate, clinical trial management, Manufacturing, Production, Regulatory, Quality, Quality Assurance, and Quality Control
Locations
-
Primary
London, GB
-
901 4th St N
St Petersburg, Florida 33701, US
Employees at Global Life Science Hub
-
Christopher Antoniou
CEO & Founder of Global Life Science Hub - Life Sciences Industry Expert
-
Alexander Antoniou
CEO & Founder of AL Solutions - Headhunting Senior Executives, Life Sciences - USA & EMEA
-
Zeliha Y.
Şu okulda öğrenci: Uludağ Üniversitesi
-
Kayleigh Stephens
Accounts & Operations Manager at AL Solutions
Updates
-
Pharmacosmos will acquire G1 Therapeutics, Inc. and its FDA-approved drug Cosela in a $𝟒𝟎𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐝𝐞𝐚𝐥. Pharmacosmos offered $𝟕.𝟏𝟓 𝐩𝐞𝐫 𝐬𝐡𝐚𝐫𝐞, a 68% premium over G1's August 6 closing price. Cosela, approved in 2021, reduces bone marrow damage from certain chemotherapy treatments and generated $𝟒𝟔.𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 in sales last year. The deal is expected to close by the end of the third quarter. https://lnkd.in/euwNkiHk #Pharmaceuticals #BiotechAcquisition #FDAApproval #Oncology #MarketTrends
-
Global Life Science Hub is offering a complimentary 𝐒𝐚𝐥𝐚𝐫𝐲 𝐒𝐮𝐫𝐯𝐞𝐲, offering valuable insights into market trends within 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬, 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲, 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐀𝐬𝐬𝐮𝐫𝐚𝐧𝐜𝐞, 𝐚𝐧𝐝 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 across the EU and USA. With salaries changing significantly in the industry, it's essential to stay up-to-date. Industry leaders looking to stay informed on the latest trends and benchmarks in these key areas of the life sciences sector are encouraged to click the link below! https://lnkd.in/e-Kgiqbf #LifeScienceInsights #SalarySurvey #MarketTrends #IndustryData #PharmaceuticalIndustry
Salary Survey - GLS Hub
glshub.com
-
Boehringer Ingelheim is acquiring 𝐍𝐞𝐫𝐢𝐨 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 for up to $𝟏.𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 to enhance its immuno-oncology portfolio with Nerio's preclinical checkpoint inhibitors. These small molecules, which inhibit 𝐏𝐓𝐏𝐍𝟏 and 𝐏𝐓𝐏𝐍𝟐, show promise in enhancing anti-tumor activity. Boehringer aims to use them both as monotherapies and in combination with its oncology therapies. This deal expands Boehringer's cancer treatment options, adding to its 𝟏𝟏 𝐩𝐡𝐚𝐬𝐞 𝟏 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬. https://lnkd.in/eY3S6heZ #BoehringerIngelheim #NerioTherapeutics #Oncology #CheckpointInhibitors #CancerResearch #ImmunoOncology #MergersAndAcquisitions #Biotech #Pharma #CancerTreatment
Boehringer inks $1.3B acquisition of Nerio and its preclinical checkpoint inhibitors
fiercebiotech.com
-
GSK has partnered with Flagship Pioneering, investing $𝟏𝟓𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐮𝐩𝐟𝐫𝐨𝐧𝐭 in a respiratory and immunology research project. The goal is to identify up to 𝟏𝟎 𝐧𝐞𝐰 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐚𝐧𝐝 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬, with GSK holding exclusive development rights. Flagship could receive up to $𝟕𝟐𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 per program in milestones and royalties, potentially totalling over $𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. The collaboration aims to advance promising scientific concepts and may expand into other therapeutic areas. GSK’s Chief Scientific Officer, Tony Wood, highlighted the partnership’s potential to accelerate innovation and deliver transformative treatments. https://lnkd.in/eVJn73j2 #GSK #FlagshipPioneering #Biotech #Pharma #RespiratoryHealth #Immunology #Innovation #Research #Collaboration #Healthcare #Medicine #Vaccines #Biopharma #ClinicalDevelopment
GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact
fiercebiotech.com
-
Owens & Minor is acquiring Rotech Healthcare Holdings for $1.36 billion. This deal aims to boost Owens & Minor's sales by adding Rotech’s home medical equipment, including sleep and oxygen devices, hospital beds, and wheelchairs. Rotech, with over 𝟒,𝟐𝟎𝟎 𝐞𝐦𝐩𝐥𝐨𝐲𝐞𝐞𝐬 𝐢𝐧 𝟒𝟔 𝐬𝐭𝐚𝐭𝐞𝐬, will enhance Owens & Minor's product suite. The acquisition aligns with Owens & Minor's goal of reaching $𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐝𝐢𝐫𝐞𝐜𝐭 𝐬𝐚𝐥𝐞𝐬 𝐛𝐲 𝟐𝟎𝟐𝟖 and is expected to close by the end of 2024. #HealthcareAcquisition #MedicalEquipment #PharmaIndustry #SleepApnea #HealthcareExpansion https://lnkd.in/djJxCyBQ
Owens & Minor inks $1.36B takeover of Rotech
medtechdive.com
-
Pharma giant GSK has signed a non-exclusive licensing deal with CDMO Touchlight for its "𝐝𝐨𝐠𝐠𝐲𝐛𝐨��𝐞 𝐃𝐍𝐀" manufacturing technology. The agreement includes upfront payments, access fees, milestone payments, and royalties on 𝐦𝐑𝐍𝐀 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬. Touchlight's technology, a minimal, linear DNA structure, eliminates bacterial sequences, enhancing speed and scalability in producing vaccines, therapeutics, and gene therapies. Jonny Ohlson, founder of Touchlight, emphasized the tech's importance in the advanced therapy supply chain for next-generation mRNA therapeutics. https://lnkd.in/dJG299Vs #PharmaInnovation #DNAtech #Biotech #GSK #mRNA
GSK inks deal with CDMO Touchlight for access to its ‘doggybone DNA’ tech
fiercepharma.com
-
Agilent Technologies is set to acquire Canadian specialty CDMO BIOVECTRA for $𝟗𝟐𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 in a deal expected to close by the end of 2024, pending regulatory approvals. This acquisition will enhance Agilent's contract manufacturing capabilities for 𝐨𝐥𝐢��𝐨𝐧𝐮𝐜𝐥𝐞𝐨𝐭𝐢𝐝𝐞𝐬 and 𝐂𝐑𝐈𝐒𝐏𝐑 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, integrating Biovectra into the Agilent Diagnostics and Genomics Group. Biovectra, which reported $𝟏𝟏𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫, manufactures biologics, potent APIs, and other molecules for targeted therapies and serves over 𝟏𝟎𝟎 𝐚𝐜𝐭𝐢𝐯𝐞 𝐜𝐥𝐢𝐞𝐧𝐭𝐬, including 𝟏𝟖 𝐨𝐟 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝'𝐬 𝐭𝐨𝐩 𝟐𝟎 𝐩𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬. https://lnkd.in/gNTjB-Bf #PharmaMergers #BiotechAcquisition #CDMO #CRISPR #Biomanufacturing
Agilent Technologies lays out $925M to acquire Canadian specialty CDMO Biovectra
fiercepharma.com
-
𝐓𝐡𝐚𝐧𝐤 𝐲𝐨𝐮 𝐭𝐨 𝐨𝐮𝐫 𝟏𝟎,𝟎𝟎𝟎 𝐅𝐨𝐥𝐥𝐨𝐰𝐞𝐫𝐬!!🥳 We're grateful to our 10,000 followers who have helped us achieve another incredible milestone. While navigating a turbulent industry market, we've collectively forged strong new partnerships, expanded our network with world-class candidates, and are quickly becoming recognised as a go-to partner for biopharma operations. As we gear up for a record-breaking Q3, we couldn't be more thankful for the support from our partners, candidates, and followers over the past 2.5 years. Thank you all for being part of our journey! #manufacturing #quality #regulatory #lifescience #hiring #biopharma #drugdevelopment
-
-
LOTTE BIOLOGICS has begun construction on a $𝟑.𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲 𝐢𝐧 𝐈𝐧𝐜𝐡𝐞𝐨𝐧, 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚, as part of its goal to become a 𝐭𝐨𝐩 𝟏𝟎 𝐂𝐃𝐌𝐎 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞. The new site will cover over 𝟐.𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐪𝐮𝐚𝐫𝐞 𝐟𝐞𝐞𝐭 and feature three production plants with a total 𝐜𝐚𝐩𝐚𝐜𝐢𝐭𝐲 𝐨𝐟 𝟑𝟔𝟎,𝟎𝟎𝟎 𝐥𝐢𝐭𝐞𝐫𝐬. This flagship project underscores Lotte’s ambitious growth plans in the CDMO industry. https://lnkd.in/gkeE9SEr #Biopharma #Manufacturing #CDMO #Biotech #SouthKorea
CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals
fiercepharma.com